Jason Bock, PhD, has a history of building organizations to develop biologic therapeutics intended to impact patients. He is CEO of CTMC, a joint division between MD Anderson Cancer Center + Resilience formed in May 2022. CTMC was created to bring together innovative academic science with industrial drug development and advanced manufacturing capabilities to rapidly enable cell therapies that impact patients.
In 2019, Dr. Bock was recruited by MD Anderson to build the Biologics Development group, which serves as an internal biotech to support development of MDACC-invented biologics. The group purchased a 60,000 SF cell therapy manufacturing facility in the Texas Medical Center to bring together innovative academic science with industrial drug development and advanced manufacturing capabilities to rapidly enable cell therapies that impact patients.
Previously Dr. Bock was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. During his 10 years at Teva, he grew the Biologics team to over 600 employees, brought 15 novel drugs through preclinical development into clinical studies, and drove three biologics through the clinic into commercialization globally. He joined Teva, through the acquisition of CoGenesys, a private biotech firm that was a spinoff from Human Genome Sciences (HGS), where he began his career.
Dr. Bock received a BS in Biology from MIT and a PhD in Molecular and Cellular Physiology from Stanford University.
